Oncolytic virus preclinical toxicology studies-Reference-Cited by-同舟云学术

Oncolytic virus preclinical toxicology studies

Published:2022-11-07 Issue:5 Volume:43 Page:620-648
ISSN:0260-437X
Container-title:Journal of Applied Toxicology
language:en
Short-container-title:J of Applied Toxicology

Author:

Rasa Agnija¹^ORCID,Alberts Pēteris¹^ORCID

Affiliation:

1. R&D Rigvir Riga Latvia

Publisher

Wiley

Subject

Toxicology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jat.4408

Reference123 articles.

1. Editorial: Oncolytic Virus and Gene Thearapy Application: Update 2018

2. The advent of oncolytic virotherapy in oncology: The Rigvir® story

3. Amgen. (2015).Amgen Inc. IMLYGIC (talimogene laherparepvec). Suspension for intralesional injection. Highlights of prescribing information.https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/imlygic/imlygic_pi.pdfAccessed 17 May 2021.

4. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

5. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenic cell death-based oncolytic virus therapy: A sharp sword of tumor immunotherapy;European Journal of Pharmacology;2024-10

2. Shifting cold to hot tumors by nanoparticle-loaded drugs and products;Clinical and Translational Oncology;2024-06-26

3. Oncolytic virus-based combination therapy in breast cancer;Cancer Letters;2024-03

4. Overview of tumor immunotherapy based on approved drugs;Life Sciences;2024-03

5. The role of immune cells in resistance to oncolytic viral therapy;Mathematical Biosciences and Engineering;2024